Skip to main content
Bulletin

Nominee Directors in Private Equity and Venture Capital: Navigating Issues Raised by Confidential Company Information

Fasken
Reading Time 1 minute read
Subscribe
Share
  • LinkedIn

Overview

Capital Markets and Mergers & Acquisitions Bulletin

Nominee directors are central to private equity and venture capital investment strategies.

But what should take precedence: the confidentiality of board deliberations or the investor’s expectation of information?

A recent ruling by the Delaware Court of Chancery highlights that Canadian and Delaware corporate law differ relatively significantly on this important issue.

Writing in The M&A Lawyer (PDF, 184KB), we highlight what investors in the Canadian market, and their nominee directors, should know about the sharing of confidential company information in Canada.

We then provide key practice points to consider when appointing nominee directors amid Canadian investment transactions.

For more of Fasken’s M&A insights, visit our M&A Knowledge Centre.

 

Contact the Authors

If you have any questions regarding this insight, please contact the authors or any other member of our Capital Markets and Mergers & Acquisitions group.

Contact the Authors

Authors

  • Gesta A. Abols, Partner | Co-Leader, cross border and international practice, Toronto, ON, +1 416 943 8978, gabols@fasken.com
  • Perry Feldman, Partner, Calgary, AB, +1 403 261 5396, pfeldman@fasken.com
  • Marco Maduri, Associate, Vancouver, BC, +1 604 631 4853, mmaduri@fasken.com
  • Marie-Christine Valois, Partner, Montréal, QC, +1 514 397 7413, mvalois@fasken.com
  • Paul Blyschak, Counsel, Calgary, AB, +1 403 261 9465, pblyschak@fasken.com

    Subscribe

    Receive email updates from our team

    Subscribe